Atriva

Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

Press releases

Press
20. October 2020

HTGF portfolio company: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the company’s lead product candidate against influenza and COVID-19Atriva’s ATR-002 molecule is the only host-cell targeting antiviral therapeutic specifically developed to treat severe respiratory infections caused by RNA (ribonucleic acid) viruses – it may prevent progression to critical-stage COVID-19 in hospitalised patients and holds stro
 
Press
11. August 2020

Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

Round led by existing investors Meneldor and High-Tech GründerfondsProceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infectionsATR-002 mode of action inhibits viral propagation of respiratory RNA viruses and prevents the cytokine storm, as demonstrated in preclinical studies Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral the
 
Press
21. September 2017
Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage
The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage. Atriva Therapeutics stands for the next generation of
 

Info & Contact

Dr. Rainer Lichtenberger, CEO
Web:
www.atriva-therapeutics.com

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1
72072 Tübingen

In portfolio

27. Dec 2016

HTGF Manager

 
Dr. Frank Hensel, Principal / Authorized signatory